Dianthus Therapeutics DNTH Other Costs — Research And Development Expense
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's other costs — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dianthus Therapeutics's other costs — research and development expense?
- Dianthus Therapeutics (DNTH) reported other costs — research and development expense of $1.49M in Q1 2026.
- How has Dianthus Therapeutics's other costs — research and development expense changed year-over-year?
- Dianthus Therapeutics's other costs — research and development expense increased by 25.5% year-over-year, from $1.19M to $1.49M.
- What does other costs — research and development expense mean?
- This metric represents the aggregate costs incurred by the company for early-stage research activities and exploratory development projects that are not directly attributable to a specific lead clinical program. It captures the foundational investment in scientific discovery and platform technology development necessary to build a sustainable pipeline. Monitoring this expense helps investors assess the company's commitment to long-term innovation and the scalability of its underlying research engine.